ANTIHYPERTENSIVE & LIPID LOWERING THERAPY TO PREVENT HEART ATTACK TRIAL

据估计，美国有5000万人血液高涨 血压(收缩压[SBP]=/&>140毫米汞和/或舒张压 [DBP]=/&>90毫米汞柱)，或正在服用降压药。全 考虑的因素和保持不变的情况下， 用100美元/病人年的药物治疗2500万名患者 与500美元/患者相比，一年的治疗费用是10美元 十亿美元。高血压在非洲人中更为常见 美国人比高加索人，其后遗症也更常见 非裔美国人。因此，降血压和降血脂作用于 预防心脏病发作试验(ALLHAT)，一个全国性的，以实践为基础的， 抗高血压药物治疗的随机临床试验 和降胆固醇，以防止心脏病发作在特定的子集 40,000名高危高血压患者，其中至少55%是非洲人 美国人。抗高血压治疗臂的目的是 确定致命性冠心病和冠心病的综合发病率 利尿剂治疗和三次治疗之间的非致命性心肌梗死 替代的(且更昂贵的)高血压药物治疗。 降脂治疗臂的目的是确定是否 降低中度高胆固醇血症男性的血清胆固醇和 60岁及以上的女性使用特定的3-羟甲基戊二酰辅助剂 酶A还原酶抑制剂，将降低所有原因的死亡率 一组接受“常规护理”的对照组。两者的次要目标 试验部分是比较它们各自治疗的效果 关于心血管死亡率、主要发病率、医疗费用和 与健康相关的生活质量。

An estimated 50 million people in the United States have high blood pressure (systolic blood pressure [SBP] =/> 140mmHg and/or diastolic BP [DBP] =/> 90mmHg), or are taking antihypertensive medications. All factors considered and remaining constact, the incremental cost of treating 25 million patients with a drug costing $100/patient-year of therapy compared to one costing $500/patient-year of therapy is $10 billion. Hypertension is considerably more common among African Americans than Caucasians, and its sequelae are also more frequent among African Americans. Thus, the Antihypertensive and Lipid-lowering to Prevent Heart Attack Trial (ALLHAT), a nation-wide, practice-based, randomized, clinical trial of antihypertensive pharmacological treatments and cholesterol-lowering to prevent heart attack in a specific subset of 40,000 high-risk hypertensive patients, is to include at least 55% African Americans. The purpose of the antihypertensive treatment arm is to determine if the combined incidence of fatal coronary heart disease and non-fatal myocardial infarction between diuretic treatment and three alternative (and more expensive) hypertensive pharmacological treatments. The purpose of the lipid-lowering treatment arm is to determine if lowering serum cholesterol in moderately hypercholesterolemic men and women aged 60 years and older with a specific 3-hydroxymethylglutaryl co- enzyme A reductase inhibitor, will reduce all-cause mortality as compared to a control group receiving "usual care." Secondary objectives of both trial components are to compare the effects of their respective treatment regimens on cardiovascular mortality, major morbidity, health costs, and health-related quality of life.